You are here

Drug Screening for Nakajo-Nishimura Syndrome

A recent STEM CELLS Translational Medicine article from the lab of Megumu K. Saito (Kyoto University, Kyoto, Japan) identified a histone deacetylase inhibitor as a potentially effective inhibitor of inflammatory chemokine overproduction in Nakajo‐Nishimura syndrome, an autoinflammatory disease, via a high‐throughput screening using pluripotent stem cell‐derived monocytic cell lines. Kase et al. believe that this study proves the validity of their screening system as a versatile platform for the discovery of candidate compounds for the treatment of congenital immunological disorders associated with monocytic lineage cells.